Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

被引：0
|
作者：
Qin, Shukui
Bai, Yuxian
Wang, Zishu
Chen, Zhendong
Xu, Ruihua
Xu, Jianming
Zhang, Hongmei
Chen, Jia
Yuan, Ying
Liu, Tianshu
Yang, Lin
Zhong, Haijun
Chen, Donghui
Shen, Lin
Hao, Chunyi
Fu, Deliang
Cheng, Ying
Yang, Jianwei
Bai, Xian Hong
Li, Jin
机构：
[1] Jinling Hosp, Ctr Canc, Dept Med Oncol, Nanjing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Anhui Med Univ, Hosp 2, Hefei, Anhui, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[6] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[7] Air Force Med Univ PLA, Xijing Hosp, Xian, Peoples R China
[8] Jiangsu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[9] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[12] Univ Chinese Acad Sci, Chinese Acad Sci, Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med,Canc Hos, Hangzhou, Peoples R China
[13] Shanghai Jiao Tong Univ, Peoples Hosp 1, Sch Med, Dept Oncol, Shanghai, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[15] Beijing Canc Hosp, Beijing, Peoples R China
[16] Fudan Univ, Pancreat Dis Inst, Huashan Hosp, Dept Pancreat Surg, Shanghai, Peoples R China
[17] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[18] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Peoples R China
[19] Biotech Pharmaceut Ltd Corp, Beijing, Peoples R China
[20] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone:: A randomized multicenter phase III clinical trial -: SAKK 44/00-CECOG/PAN.1.3.001
    Bernhard, Juerg
    Dietrich, Daniel
    Scheithauer, Werner
    Gerber, Daniela
    Bodoky, Gyo Rgy
    Ruhstaller, Thomas
    Glimelius, Bengt
    Bajetta, Emilio
    Schueller, Johannes
    Saletti, Piercarlo
    Bauer, Jean
    Figer, Arie
    Pestalozzi, Bernhard C.
    Hne, Claus-Henning Ko
    Mingrone, Walter
    Stemmer, Salomon M.
    Tamas, Karin
    Kornek, Gabriela V.
    Koeberle, Dieter
    Herrmann, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3695 - 3701
  • [32] A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
    Middleton, Gary William
    Valle, Juan W.
    Wadsley, Jonathan
    Propper, David
    Coxon, Fareeda Y.
    Ross, Paul J.
    Madhusudan, Srinivasan
    Roques, Tom
    Cunningham, David
    Corrie, Philippa
    Greenhalf, William
    Shaw, Victoria
    Cox, Trevor F.
    Silcocks, Paul
    Nanson, Gemma
    Neoptolemos, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
    Middleton, Gary William
    Valle, Juan W.
    Wadsley, Jonathan
    Propper, David
    Coxon, Fareeda Y.
    Ross, Paul J.
    Madhusudan, Srinivasan
    Roques, Tom
    Cunningham, David
    Corrie, Philippa
    Greenhalf, William
    Shaw, Victoria
    Cox, Trevor F.
    Silcocks, Paul
    Nanson, Gemma
    Neoptolemos, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [34] Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) plus /- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study
    Marino, D.
    Filippi, R.
    Cereda, S.
    Belli, C.
    Spadi, R.
    Nasti, G.
    Montano, M.
    Amatu, A.
    Lutrino, E.
    Cagnazzo, C.
    Ferrari, L.
    Siena, S.
    Ciuffreda, L.
    Reni, M.
    Aglietta, M.
    Leone, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 90 - 91
  • [35] RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
    Ko, Andrew H.
    Murphy, Patrick B.
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Frank A.
    Womack, Mark S.
    Xiong, Henry Q.
    Waterhouse, David M.
    Tempero, Margaret A.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [36] CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)
    Riess, H.
    Neuhaus, P.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
  • [37] CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)
    Neuhaus, P.
    Riess, H.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
    Su, M-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1465
  • [39] A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL WITH VEGFR2-EPITOPE PEPTIDE AND GEMCITABINE FOR PATIENTS WITH LOCALLY ADVANCED, METASTATIC, OR UNRESECTABLE PANCREATIC CANCER: PEGASUS-PC STUDY
    Yamaue, H.
    Miyazawa, M.
    Mizuno, N.
    Okusaka, T.
    Fukutomi, A.
    Ishii, H.
    Ohkawa, S.
    Furukawa, M.
    Maguchi, H.
    Ikeda, M.
    Nishio, K.
    Ohashi, Y.
    Tsunoda, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 74 - 74
  • [40] A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01)
    Jin, Gang
    Guo, Shiwei
    Xu, Jianming
    Liu, Rongrui
    Liang, Qianqian
    Yang, Yong
    Guo, Baohong
    Xu, Yiqi
    Xia, Binyan
    Zhang, Chao
    Zhu, Shengxia
    Xu, Ting
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345